FDA Approval for Wound Gel

RNS Number : 1813D

Advanced Medical Solutions Grp PLC

11 September 2008

 



For Immediate Release

11 September 2008

Advanced Medical Solutions Group plc

('AMS' or 'the Group')

510(k) approval for silver wound gel 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, is pleased to announce that its silver anti-microbial wound gel has received 510(k) approval from the Food & Drug Administration (FDA), allowing the product to be marketed in the US.

This approval gives AMS the opportunity to target a niche but growing segment of the advanced woundcare market via the Group's existing routes to market. AMS's wound gel contains silver, which is widely recognised as a safe and effective anti-microbial agent for the control of infection from a wide range of micro-organisms.

The silver anti-microbial wound gel has gained 510(k) approval for the management of dry to moderate exuding, partial to full thickness wounds including pressure ulcers, leg ulcers, diabetic ulcers, graft and donor sites, post-operative surgical wounds, trauma wounds, first and second degree burns, and abrasions and lacerations.

Commenting on this 510(k) approval, Don Evans, CEO of Advanced Medical Solutions, said:

'We have built up a very successful silver alginate business and this 510(k) approval for our silver anti-microbial wound gel provides us with another technology for the delivery of silver. We intend to commercialise this niche opportunity within advanced woundcare through our existing partner base during 2009.'

For further information, please contact:

Advanced Medical Solutions Group plc	[phone]
Don Evans, Chief Executive Officer
Mary Tavener, Group Finance Director
www.admedsol.com
Buchanan Communications	[phone]
Mark Court / Mary-Jane Johnson / Stasa Filiplic
Landsbanki Securities (UK) Ltd Shaun Dobson, Claes Spang	[phone]

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.

In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4% of Corpura BV in May 2008 strengthened AMS' position in hydrophilic polyurethane foam - the largest and fastest growing segment of the advanced woundcare market

AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection. 

AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.

 

END

 

 

MSCBLGDCGXBGGIG